Myendom is the first highly accurate non-invasive test for the screening of endometrial cancer and precancerous lesions.
What can it detect?
The Myendom screening test can detect abnormalities which, if confirmed through a diagnostic method, allow the early detection of endometrial cancer. If discovered early on, endometrial cancer can be treated less invasively and more effectively.
Who is the test recommended for
- Women of childbearing age with abnormal vaginal bleeding, abnormal endometrial thickening (≥12 mm)
- Peri / postmenopausal women with abnormal vaginal bleeding, abnormal endometrial thickening (≥5 mm)
- Duration of menstrual flow greater than 7 days
- Taking Tamoxifen (active ingredient in non-steroidal anti-estrogen drugs)
- Women with Lynch Syndrome (hereditary non-polyposis colorectal cancer)
- Personal history of breast or ovarian cancer
- Family history of endometrial cancer (mothers – daughters – sisters)
- Obese or heavily overweight women
Why Undergo Screening?
THE IMPORTANCE OF EARLY DIAGNOSIS
Early diagnosis is of vital importance because it makes therapy less invasive and, at the same time, more effective.
Risk factors are quite general and cross-cutting in the general population, both men and women.
Overweight women are at increased risk for endometrial cancer. Some studies have shown that in obese women the risk is even 5 times higher than in normal weight peers. The so-called metabolic syndrome (diabetes, obesity, hypertension) also increases the risk of developing endometrial cancer.
Unbalanced estrogen activity from progesterone increases the risk of developing endometrial cancer.
The risk, therefore, increases in all cases in which exposure to estrogen increases:
- early menarche
- late menopause
- absence of pregnancies
- taking tamoxifen
- ovarian polycystosis
- estrogen-only hormone replacement therapy (HRT)
Women with Lynch syndrome have a high risk (one in two) of developing endometrial cancer later in life.
This hereditary syndrome causes about 5% of all endometrial cancers.
A history of breast or ovarian cancer or a family history of endometrial cancer (mother, sister or daughter) increases the risk of developing one.
STATISTICAL INFORMATION ON ENDOMETRIC CANCER
- It is the fifth most diagnosed cancer in women
- It is the most common among gynecological cancers
- It is more common in the 50-70 age group
Advantages of the test
- It is the first highly accurate non-invasive test for endometrial cancer screening
- It is able to effectively distinguish uterine fibroids from endometrial cancer
- The ability of the test to correctly identify an anomaly is 88%
- The ability of the test to correctly identify a healthy subject is 93%
How the test is performed
The patient’s DNA is used to perform the Myendom test.
The DNA is extracted from a sample of exfoliated cells taken at the height of the uterine endo-exocervical junction and subjected to a specific analysis to detect any methylation abnormalities in endometrial cancer marker genes (CDO1-CELF4).
Request the test
To request Myendom or to obtain further information on the test, fill out the form below, or call +971 (0)4 375 7220 . Our biologists will respond to your requests without any commitment on your part.
(*) Required fields